Investigating how Venetoclax behaves in the body for patients with Acute Myeloid Leukemia
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
This study is testing how the drug Venetoclax works in the body of adults with Acute Myeloid Leukemia in Taiwan, especially looking at how food and other medications might change its effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04613622 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the pharmacokinetics of Venetoclax, a treatment for Acute Myeloid Leukemia (AML), specifically in the Chinese population. It will assess how factors like dietary fat and the use of certain medications affect the drug's plasma concentration. The research will involve adult patients who are receiving Venetoclax treatment at the National Taiwan University Hospital from August 2020 to December 2025. The findings could help clarify the drug's efficacy and safety in a demographic that has been underrepresented in previous studies.
Who should consider this trial
Good fit: Ideal candidates are adult patients aged 20 and older who are receiving or will receive Venetoclax treatment at the National Taiwan University Hospital.
Not a fit: Patients who are unable to cooperate with blood drawing or have not submitted informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the appropriate use of Venetoclax for AML patients in the Chinese population, potentially improving treatment outcomes.
How similar studies have performed: While there have been studies on Venetoclax, this specific investigation into its pharmacokinetics in the Chinese population is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 20 year-old) * Patients who meet the above criteria and have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from August 2020 to December 2025 Exclusion Criteria: * Patients who are unable to cooperate with blood drawing * Patients who have not submit the informed consent
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Shu-Wen Lin, Pharm.D
- Email: shuwenlin@ntu.edu.tw
- Phone: 886-2-33668782
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.